Enormous competitive advantages through cannabinoid extracts and isolates from own production. The German industrial hemp and cannabis group SYNBIOTIC SE…
Ilesol Pharmaceuticals is proud to announce the launch of new products in our line-up and brand new web site. In…
Ilesol Pharmaceuticals is proud to announce that EIHA’s CBD isolate dossier, RP427, has finally been validated by the UK’s Food…
Law Library of US Congress Releases Comprehensive Global Hemp Regulation Report The Law Library of Congress has released an…
Diabetic cardiomyopathy (DCM) is a prevalent cardiovascular complication arising from diabetes, characterized by cardiac dysfunction, fibrosis, oxidative stress, inflammation, and…
The latest scientific findings have shed light on the role of the cannabinoid receptor in reducing negative ketamine side effects,…
Ilesol Pharmaceuticals has launched three new skincare products as a part of our Skin Greens collection. The new products are…
CBD is safe and tolerable for short-term use for a maximum of 30 days at a maximum dose of 200…
On 28th June 2022, the European Industrial Hemp Association (EIHA) representatives joined the info-session organized by the European Food Safety…
The first human study on the efficacy of topical CBD for the treatment of thumb basal joint arthritis-related pain published…
On June 7, 2022, the European Fooda Safety Authority (EFSA) published a statement summarising the state of knowledge on the…
As was the case in other countries, over-the-counter CBD products in the UK have proved to be substandard. A recent…
